1.Issaq HJ, Nativ O, Waybright T, et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. The Journal of urology. 2008;179(6):2422–2426.
2.van der Poel HG, Debruyne FM. Can biological markers replace cystoscopy? An update. Current opinion in urology. 2001;11(5):503–509.
3.Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urologic oncology. 2006;24(4):326–337.
4.Siu KW, DeSouza LV, Scorilas A, et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res. 2009;8(8):3797–3807.
5.Lin L, Huang Z, Gao Y, et al. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery. Proteomics. 2012;12(14):2238–2246.
6.Lewis GD, Wei R, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. The Journal of clinical investigation. 2008;118(10):3503–3512.
7.Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15(2):431–440.
8.Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910–914.
9.Hirayama A, Kami K, Sugimoto M, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69(11):4918–4925.
10.Zhang A, Sun H, Yan G, Wang P, Wang X. Mass spectrometry-based metabolomics: applications to biomarker and metabolic pathway research. Biomedical chromatography: BMC. 2016;30(1):7–12.
11.Pasikanti KK, Esuvaranathan K, Ho PC, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res. 2010;9(6):2988–2995.
12.Monteiro MS, Barros AS, Pinto J, et al. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma. Sci Rep. 2016;6:37275.
13.Huang Z, Lin L, Gao Y, et al. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Molecular & cellular proteomics: MCP. 2011;10(10):M111.007922.
14.Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget. 2014;5(6):1635–1645.
15.Wittmann BM, Stirdivant SM, Mitchell MW, et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 2014;9(12):e115870.
16.Zhou Y, Song R, Ma C, et al. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method. Oncotarget. 2017;8(13):20719–20728.
17.Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS. 2011;15(5):293–303.
18.Falegan OS, Ball MW, Shaykhutdinov RA, et al. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma. Metabolites. 2017;7(1).
19.Luo P, Yin P, Hua R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2017.
20.Chen J, Zhao X, Fritsche J, et al. Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Anal Chem. 2008;80(4):1280–1289.
21.Zhang J, Yang W, Li S, et al. An intelligentized strategy for endogenous small molecules characterization and quality evaluation of earthworm from two geographic origins by ultra-high performance HILIC/QTOF MS(E) and Progenesis QI. Analytical and bioanalytical chemistry. 2016;408(14):3881–3890.
22.Armitage EG, Ciborowski M. Applications of Metabolomics in Cancer Studies. Advances in experimental medicine and biology. 2017;965:209–234.
23.Amara CS, Vantaku V, Lotan Y, Putluri N. Recent advances in the metabolomic study of bladder cancer. Expert review of proteomics. 2019;16(4):315–324.
24.Piyarathna DWB, Rajendiran TM, Putluri V, et al. Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. European urology focus. 2018;4(6):907–915.
25.Lee MY, Yeon A, Shahid M, et al. Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. Oncotarget. 2018;9(17):13231–13243.
26.Catchpole G, Platzer A, Weikert C, et al. Metabolic profiling reveals key metabolic features of renal cell carcinoma. Journal of cellular and molecular medicine. 2011;15(1):109–118.
27.Sato T, Kawasaki Y, Maekawa M, et al. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. International journal of cancer. 2019.
28.Wettersten HI, Hakimi AA, Morin D, et al. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer research. 2015;75(12):2541–2552.
29.Ganti S, Taylor SL, Kim K, et al. Urinary acylcarnitines are altered in human kidney cancer. International journal of cancer. 2012;130(12):2791–2800.
30.Mondul AM, Moore SC, Weinstein SJ, et al. Serum Metabolomic Response to Long-Term Supplementation with all-rac-alpha-Tocopheryl Acetate in a Randomized Controlled Trial. Journal of nutrition and metabolism. 2016;2016:6158436.
31.Al-Zalabani AH, Stewart KF, Wesselius A, Schols AM, Zeegers MP. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. European journal of epidemiology. 2016;31(9):811–851.
32.Wang YY, Wang XL, Yu ZJ. Vitamin C and E intake and risk of bladder cancer: a meta-analysis of observational studies. International journal of clinical and experimental medicine. 2014;7(11):4154–4164.
33.Nikiforova NV, Kirpatovsky VI, Darenkov AF, Chumakov AM, Sevrukov EA, Darenkov SP. Liposoluble vitamins E and A in human renal cortex and renal cell carcinomas. Nephron. 1995;69(4):449–453.
34.Denkert C, Budczies J, Kind T, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer research. 2006;66(22):10795–10804.
35.Sahu D, Lotan Y, Wittmann B, Neri B, Hansel DE. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer medicine. 2017;6(9):2106–2120.
36.Cheng Y, Yang X, Deng X, et al. Metabolomics in bladder cancer: a systematic review. International journal of clinical and experimental medicine. 2015;8(7):11052–11063.